View Pharmacist Webcast

Drug Conviction Data in KASPER: What is a Pharmacist to Do?

Activity Details
  • Credit Amounts:
    • CPE: 1.50
    • Other: 1.50
  • Cost: Free
  • Release: Jan 15, 2020
  • Expires: Jan 14, 2023
  • Estimated Time to Complete:
    1 Hour(s)  30 Minutes
  • System Requirements:
  • Average User Rating:
    (2 Ratings)

Faculty

Patricia R.  Freeman Patricia R. Freeman, RPh, PhD, FAPhA
Associate Professor, Pharmacy Practice and Science
Director, Center for the Advancement of Pharmacy Practice (CAPP)
Faculty Associate, Institute for Pharmaceutical Outcomes and Policy (IPOP)
University of Kentucky College of Pharmacy
Lexington, Kentucky

Dana L.  Quesinberry Dana L. Quesinberry, JD
Program Manager, Kentucky Drug Overdose Prevention Program
Health Policy and Program Evaluator
Kentucky Injury Prevention and Research Center
Lexington, Kentucky

Needs Statement

Kentucky State Senate Bill 32 (2017) mandated that drug conviction data be made available in KASPER effective July 1, 2018. Education to prescribers and dispensing pharmacists on how to interpret this data in the context of patient care and opioid prescribing/dispensing is needed to prevent unintended consequences.

Target Audience

This activity is designed for pharmacists who dispense controlled substances and any other interested healthcare professionals.

Objectives

Kentucky Senate Bill 32 and Drug Conviction Data in KASPER: What Have We Learned?
Upon completion of this educational activity, participants will be able to:

  • Discuss implications of SB 32 that made drug conviction data available in KASPER effective July 1, 2018
  • Review results of Kentucky prescriber and dispenser survey on intent to use drug conviction data in KASPER
  • Assess current data regarding the use of drug conviction data in KASPER by pharmacists and prescribers

Drug Conviction Data in KASPER: What Does it Mean?
Upon completion of this educational activity, participants will be able to:

  • Describe the types of drug-related charges in Kentucky
  • Review example drug conviction data and describe its content and interpretation
  • Identify limitations of drug conviction data
  • Evaluate nuances of interpreting drug conviction data and legal implications

Drug Conviction Data in KASPER: What Should I Do?
Upon completion of this educational activity, participants will be able to:

  • Discuss the impact of criminal conviction data on pharmacists’ attitudes and resulting patient health outcomes
  • Use example vignettes to interpret drug conviction data in the context of patient care
  • Identify strategies for making sound decisions when dispensing controlled substances to prevent unintended consequences

Accreditation

CPE
ACPEThe University of Kentucky College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This knowledge-based activity has been assigned UAN 0022-0000-20-069-H03-P and will award 1.50 contact hours (0.150 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

Statements of participation will indicate hours and CEUs based on participation and will be issued online at the conclusion of the activity. Successful completion includes completing the activity, its accompanying evaluation and/or posttest (score 70% or higher) and requesting credit online at the conclusion of the activity. Credit will be uploaded to CPE Monitor, and participants may print a statement of credit or transcript from their NABP e-profile. The College complies with the Accreditation Standards for Continuing Pharmacy Education.

Other
UK Healthcare CECentral certifies this activity for 1.50 hours of participation.

Faculty Disclosure

No speakers, planners, or content reviewers have any relevant financial relationships to disclose.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Acknowledgment

This project was supported by Grant No. 2017-PM-BX-K026 (Data-Driven Responses to Prescription Drug Misuse in Kentucky) awarded by the Bureau of Justice Assistance (BJA) to the Kentucky Injury Prevention and Research Center as bona fide agent for the Kentucky Department for Public Health.

The BJA is a component of the Department of Justice’s Office of Justice Program, which includes the Bureau of Justice Statistics, the National Institute of Justice, the Office of Juvenile Justice and Delinquency Prevention, the Office of Victims Crime, and the SMART Office.

Viewpoints or opinions in these programs are those of the authors and do not necessarily represent the official position or policies of the US Department of Justice.

CE Content Concerns

Policy

Concerns or complaints related to ACPE or ACCME standards may be submitted in writing to the Director of UK HealthCare CECentral by fax to 859-323-2920, or by mail to 2365 Harrodsburg Road, Ste B475, Lexington, KY 40504

Procedures

  • The Director or his/her designee will review, investigate, forward and/or respond to complaints and will put forth a best effort to adjudicate the issue(s), along with CECentral staff members, within two (2) weeks of receipt of the grievance or complaint.
  • If needed, concerns, complaints, or grievances will be brought before the UK HealthCare CECentral Advisory Board.
  • Issues regarding activity content also will be reviewed and addressed by the Activity Director.
  • A written decision will be issued in a timely manner by the Director of UK HealthCare CECentral or his/herdesignee.
  • Grievances will be considered when planning future activities.

Appeal Procedure

  • Persons who wish to appeal a decision should address the appeal by email, fax or in writing to the Director of UK HealthCare CECentral within two (2) weeks of receipt of the response.
  • The Director will bring the appeal to the UK HealthCare CECentral Advisory Board.
  • The results of the appeal will be sent to the participant no later than two (2) weeks following the meeting of the board.